Literature DB >> 19722626

Binding and inactivation mechanism of a humanized fatty acid amide hydrolase by alpha-ketoheterocycle inhibitors revealed from cocrystal structures.

Mauro Mileni1, Joie Garfunkle, Jessica K DeMartino, Benjamin F Cravatt, Dale L Boger, Raymond C Stevens.   

Abstract

The cocrystal X-ray structures of two isomeric alpha-ketooxazole inhibitors (1 (OL-135) and 2) bound to fatty acid amide hydrolase (FAAH), a key enzymatic regulator of endocannabinoid signaling, are disclosed. The active site catalytic Ser241 is covalently bound to the inhibitors' electrophilic carbonyl groups, providing the first structures of FAAH bound to an inhibitor as a deprotonated hemiketal mimicking the enzymatic tetrahedral intermediate. The work also offers a detailed view of the oxyanion hole and an exceptional "in-action" depiction of the unusual Ser-Ser-Lys catalytic triad. These structures capture the first picture of inhibitors that span the active site into the cytosolic port providing new insights that help to explain FAAH's interaction with substrate leaving groups and their role in modulating inhibitor potency and selectivity. The role for the activating central heterocycle is clearly defined and distinguished from that observed in prior applications with serine proteases, reconciling the large electronic effect of attached substituents found unique to this class of inhibitors with FAAH. Additional striking active site flexibility is seen upon binding of the inhibitors, providing insights into the existence of a now well-defined membrane access channel with the disappearance of a spatially independent portion of the acyl chain-binding pocket. Finally, comparison of the structures of OL-135 (1) and its isomer 2 indicates that they bind identically to FAAH, albeit with reversed orientations of the central activating heterocycle, revealing that the terminal 2-pyridyl substituent and the acyl chain phenyl group provide key anchoring interactions and confirming the distinguishing role of the activating oxazole.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19722626      PMCID: PMC2739126          DOI: 10.1021/ja902694n

Source DB:  PubMed          Journal:  J Am Chem Soc        ISSN: 0002-7863            Impact factor:   15.419


  50 in total

1.  Characterization and manipulation of the acyl chain selectivity of fatty acid amide hydrolase.

Authors:  M P Patricelli; B F Cravatt
Journal:  Biochemistry       Date:  2001-05-22       Impact factor: 3.162

2.  Hydrogen bonds with pi-acceptors in proteins: frequencies and role in stabilizing local 3D structures.

Authors:  T Steiner; G Koellner
Journal:  J Mol Biol       Date:  2001-01-19       Impact factor: 5.469

3.  Exceptionally potent inhibitors of fatty acid amide hydrolase: the enzyme responsible for degradation of endogenous oleamide and anandamide.

Authors:  D L Boger; H Sato; A E Lerner; M P Hedrick; R A Fecik; H Miyauchi; G D Wilkie; B J Austin; M P Patricelli; B F Cravatt
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-09       Impact factor: 11.205

4.  Fatty acid amide hydrolase competitively degrades bioactive amides and esters through a nonconventional catalytic mechanism.

Authors:  M P Patricelli; B F Cravatt
Journal:  Biochemistry       Date:  1999-10-26       Impact factor: 3.162

5.  Chemical and mutagenic investigations of fatty acid amide hydrolase: evidence for a family of serine hydrolases with distinct catalytic properties.

Authors:  M P Patricelli; M A Lovato; B F Cravatt
Journal:  Biochemistry       Date:  1999-08-03       Impact factor: 3.162

Review 6.  Oleamide: an endogenous sleep-inducing lipid and prototypical member of a new class of biological signaling molecules.

Authors:  D L Boger; S J Henriksen; B F Cravatt
Journal:  Curr Pharm Des       Date:  1998-08       Impact factor: 3.116

7.  Evidence for a strong sulfur-aromatic interaction derived from crystallographic data.

Authors:  R J Zauhar; C L Colbert; R S Morgan; W J Welsh
Journal:  Biopolymers       Date:  2000-03       Impact factor: 2.505

8.  Fatty acid amide hydrolase substrate specificity.

Authors:  D L Boger; R A Fecik; J E Patterson; H Miyauchi; M P Patricelli; B F Cravatt
Journal:  Bioorg Med Chem Lett       Date:  2000-12-04       Impact factor: 2.823

9.  Clarifying the catalytic roles of conserved residues in the amidase signature family.

Authors:  M P Patricelli; B F Cravatt
Journal:  J Biol Chem       Date:  2000-06-23       Impact factor: 5.157

10.  Trifluoromethyl ketone inhibitors of fatty acid amide hydrolase: a probe of structural and conformational features contributing to inhibition.

Authors:  D L Boger; H Sato; A E Lerner; B J Austin; J E Patterson; M P Patricelli; B F Cravatt
Journal:  Bioorg Med Chem Lett       Date:  1999-01-18       Impact factor: 2.823

View more
  34 in total

1.  Strategies for discovering and derisking covalent, irreversible enzyme inhibitors.

Authors:  Douglas S Johnson; Eranthie Weerapana; Benjamin F Cravatt
Journal:  Future Med Chem       Date:  2010-06       Impact factor: 3.808

2.  Fatty acid-binding proteins (FABPs) are intracellular carriers for Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD).

Authors:  Matthew W Elmes; Martin Kaczocha; William T Berger; KwanNok Leung; Brian P Ralph; Liqun Wang; Joseph M Sweeney; Jeremy T Miyauchi; Stella E Tsirka; Iwao Ojima; Dale G Deutsch
Journal:  J Biol Chem       Date:  2015-02-09       Impact factor: 5.157

3.  Biphenyl-3-yl alkylcarbamates as fatty acid amide hydrolase (FAAH) inhibitors: steric effects of N-alkyl chain on rat plasma and liver stability.

Authors:  Federica Vacondio; Claudia Silva; Alessio Lodola; Caterina Carmi; Silvia Rivara; Andrea Duranti; Andrea Tontini; Silvano Sanchini; Jason R Clapper; Daniele Piomelli; Giorgio Tarzia; Marco Mor
Journal:  Eur J Med Chem       Date:  2011-07-21       Impact factor: 6.514

4.  Intrinsic evolutionary constraints on protease structure, enzyme acylation, and the identity of the catalytic triad.

Authors:  Andrew R Buller; Craig A Townsend
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-04       Impact factor: 11.205

Review 5.  Fatty acid amide signaling molecules.

Authors:  Cyrine Ezzili; Katerina Otrubova; Dale L Boger
Journal:  Bioorg Med Chem Lett       Date:  2010-08-13       Impact factor: 2.823

6.  Discovery of PF-04457845: A Highly Potent, Orally Bioavailable, and Selective Urea FAAH Inhibitor.

Authors:  Douglas S Johnson; Cory Stiff; Scott E Lazerwith; Suzanne R Kesten; Lorraine K Fay; Mark Morris; David Beidler; Marya B Liimatta; Sarah E Smith; David T Dudley; Nalini Sadagopan; Shobha N Bhattachar; Stephen J Kesten; Tyzoon K Nomanbhoy; Benjamin F Cravatt; Kay Ahn
Journal:  ACS Med Chem Lett       Date:  2011-02-10       Impact factor: 4.345

7.  Rational design of fatty acid amide hydrolase inhibitors that act by covalently bonding to two active site residues.

Authors:  Katerina Otrubova; Monica Brown; Michael S McCormick; Gye W Han; Scott T O'Neal; Benjamin F Cravatt; Raymond C Stevens; Aron H Lichtman; Dale L Boger
Journal:  J Am Chem Soc       Date:  2013-04-12       Impact factor: 15.419

8.  A binding site for nonsteroidal anti-inflammatory drugs in fatty acid amide hydrolase.

Authors:  Laura Bertolacci; Elisa Romeo; Marina Veronesi; Paola Magotti; Clara Albani; Mauro Dionisi; Chiara Lambruschini; Rita Scarpelli; Andrea Cavalli; Marco De Vivo; Daniele Piomelli; Gianpiero Garau
Journal:  J Am Chem Soc       Date:  2012-12-21       Impact factor: 15.419

9.  Piperidinyl thiazole isoxazolines: A new series of highly potent, slowly reversible FAAH inhibitors with analgesic properties.

Authors:  Stephen O Pember; Galo L Mejia; Theodore J Price; Robert J Pasteris
Journal:  Bioorg Med Chem Lett       Date:  2016-02-22       Impact factor: 2.823

10.  X-ray crystallographic analysis of alpha-ketoheterocycle inhibitors bound to a humanized variant of fatty acid amide hydrolase.

Authors:  Mauro Mileni; Joie Garfunkle; Cyrine Ezzili; F Scott Kimball; Benjamin F Cravatt; Raymond C Stevens; Dale L Boger
Journal:  J Med Chem       Date:  2010-01-14       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.